These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 6137365)
1. Calcium antagonists and the acutely ischemic heart: experimental effects on ventricular fibrillation and enzyme release. Opie LH; Thandroyen FT; Hamm CW; Muller CA; Lloyd EA; Gordon D Eur Heart J; 1983 May; 4 Suppl C():93-100. PubMed ID: 6137365 [TBL] [Abstract][Full Text] [Related]
2. Calcium ions, drug action and the heart--with special reference to calcium antagonist drugs. Opie LH Pharmacol Ther; 1984; 25(3):271-95. PubMed ID: 6151199 [TBL] [Abstract][Full Text] [Related]
3. Calcium antagonists, ventricular fibrillation, and enzyme release in ischemic rat hearts. Opie LH; Thandroyen FT Fed Proc; 1983 May; 42(8):2465-9. PubMed ID: 6132839 [TBL] [Abstract][Full Text] [Related]
4. Protection of infarcting myocardium by slow channel inhibitors. Comparative effects of verapamil, nifedipine, and diltiazem in the coronary-ligated, isolated working rat heart. Hamm CW; Opie LH Circ Res; 1983 Feb; 52(2 Pt 2):I129-38. PubMed ID: 6831647 [No Abstract] [Full Text] [Related]
5. [Characteristics of action of various drugs blocking atrioventricular conduction (beta-blockers, verapamil, diltiazem) in constant fibrillation tachyarrhythmia. Is monotherapy optimal?]. Blagova OV; Nedostup AV Ter Arkh; 2006; 78(8):30-8. PubMed ID: 17078214 [TBL] [Abstract][Full Text] [Related]
6. Experimental antifibrillatory effects of calcium channel blockade with diltiazem: comparison with beta-blockade and nitroglycerin. Anastasiou-Nana M; Nanas J; Menlove RL; Anderson JL J Cardiovasc Pharmacol; 1984; 6(5):780-7. PubMed ID: 6209480 [TBL] [Abstract][Full Text] [Related]
7. [Is there a role for calcium antagonists when beta-adrenergic blockade therapy is contraindicated in post-myocardial infarction?]. Ennezat PV; Auffray JL; Darchis J; Rousselle M; Gonin X; Aubert JM; Bauchart JJ; Bauters C; Van Belle E; Asseman P Therapie; 2006; 61(3):191-4. PubMed ID: 16989118 [TBL] [Abstract][Full Text] [Related]
10. Pharmacological basis for the therapeutic applications of slow-channel blocking drugs. Singh BN Angiology; 1982 Aug; 33(8):492-515. PubMed ID: 7051905 [TBL] [Abstract][Full Text] [Related]
11. Calcium antagonists and prevention of ventricular fibrillation induced by transient or persistent ischemia. Timour Q; Bui-Xuan B; Aupetit JF; Freysz M; Evreux JC; Faucon G Jpn Heart J; 1997 Mar; 38(2):237-51. PubMed ID: 9201111 [TBL] [Abstract][Full Text] [Related]
12. Dissociation of cardiodepression from cardioprotection with calcium antagonists: diltiazem protects ischemic rat myocardium with a lower functional cost as compared with verapamil or nifedipine. Grover GJ; Sleph PG J Cardiovasc Pharmacol; 1989 Aug; 14(2):331-40. PubMed ID: 2476610 [TBL] [Abstract][Full Text] [Related]
13. The use of beta-adrenergic blocking agents, i.v. nitrates and calcium channel blocking agents following acute myocardial infarction. Yusuf S Chest; 1988 Jan; 93(1 Suppl):25S-28S. PubMed ID: 2891466 [No Abstract] [Full Text] [Related]
14. [Beta-adrenergic blockers and calcium antagonists in hypertrophic cardiomyopathy]. Korovina EP Klin Med (Mosk); 1998; 76(12):30-5. PubMed ID: 10067289 [TBL] [Abstract][Full Text] [Related]